Clinical Trial Update: AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations [NA]

View source ↗

Summary

The AST2818 trial in advanced non-small cell lung cancer with EGFR mutations has been terminated; no further results are provided in the update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AST2818

Snippet

Sponsor: Allist Pharmaceuticals, Inc. | Conditions: Advanced NSCLC | NA | Status: TERMINATED